Earnings at Schering-Plough Climbed 75% in 4th Quarter
549877
The drug maker Schering-Plough Corporation said yesterday that its fourth-quarter profit surged 75 percent as strong sales of its cholesterol, arthritis and allergy medicines helped offset rising research and marketing spending.
746919
Drug maker Schering-Plough Corp   on Tuesday reported a fourth-quarter loss as special  charges from its acquisition of Organon Biosciences late last  year offset sharply higher sales.
98639
Fourth-quarter earnings at the Industrial conglomerate  rose to 1.06 billion as sales rose across each of segments, with aerospace unit Sikorsky and Otis leading the way, the company said.
335265
Biogen Idec Inc.  said on Thursday that fourth-quarter earnings rose on higher sales of its cancer and multiple sclerosis drugs.
10796
Net profit in the fourth quarter rose to 753 million euros ($1.09 billion), helped by sales of the blood-thinner Plavix in the United States and cost-cutting measures, the company said.
681244
Fourth-quarter earnings rose 42 percent from a year ago as profit margins at its U.S. stores improved despite higher commodity costs.
378404
Charges hurt the quarterly results of  Johnson & Johnson, Merck & Co. and Schering-Plough Corp., but  the drugmakers' shares rose as J&J's earnings beat Wall Street  forecasts and Merck sales edged higher despite the withdrawal  of its best-selling Vioxx arthritis drug.
75799
Schering-Plough and Merck posted strong sales from their joint venture in cholesterol drugs, but otherwise their third-quarter earnings were notably different.
767949
UBS AG said Tuesday its fourth-quarter profit rose 12 percent to 2.02 billion Swiss francs (&#36;1.79 billion), driven by higher revenue from equity trading and solid income from fees on securities managed for clients.
107475
KANSAS CITY, Missouri  - Monsanto Co.  reported on Thursday that quarterly earnings jumped 71 percent, driven partly by surging sales of its genetically modified corn and other seeds.
683806
The biotech company reported net income of $833 million, or 71 cents per share, for the latest quarter.
378273
The health care products maker posted higher profit in the fourth quarter versus year-earlier results that were reduced by acquisition charges for Kos Pharmaceuticals.
595740
Schering-Plough Corp. swung to a profit in the third quarter from a loss a year ago, even as sales decline slightly in the period.
404937
Schering gets a haircut after missing earnings.
348152
The German drug maker Bayer said its third-quarter profit fell 35 percent on costs related to its acquisition of a rival, Schering, but its performance still exceeded analystsÂ expectations. Bayer earned 320 million euros ($419 million) in the three months through September, down from 493 million euros a year earlier. Sales rose 26 percent, to 7.78 billion euros ($10.2 billion). The company, based in Leverkusen, said it booked special charges totaling 139 million euros ($182 million) in the quarter, with 106 million euros ($139 million) of that mostly attributable to the integration of its health care unit with Schering. Bayer bought Schering in June in a deal worth nearly 16.9 billion euros ($22 billion) to strengthen its health care business. The company said its health care unit was Âthe principal growth engine for BayerÂs business in the third quarter,Â with sales climbing 73 percent, to 3.48 billion euros ($4.56 billion).
300389
Amgen  reported on Thursday that its fourth-quarter profit edged higher as cost cutting helped offset declining sales of its anemia drugs that have been hit with safety concerns and new restrictions on their use and insurance reimbursements.
585604
Wyeth  said on Thursday that fourth-quarter earnings rose 17 percent on higher sales of its Enbrel arthritis drug and Prevnar vaccine to prevent childhood infections.